May 2017

Fresenius Kabi Acquisitions

Fresenius Kabi will strengthen and diversify its product portfolio by acquiring Akorn and Merck KGaA's biosimilars business.  Stephan Sturm, CEO of Fresenius, said: "From a position of strength, Fresenius Kabi enhances and complements its business with two major steps. Akorn is an excellent strategic fit for Fresenius Kabi. The company's product portfolio is highly complementary to our well-developed generics business. The simultaneous entry into the biosimilars business is the right step into the right direction at the right time.